Richard Goldberg, MD

Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer.
Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouche O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Francois Emile J, Laurent Puig P, Sinicrope FA.
J Natl Cancer Inst. 2017; 109(5).

In process

A study of thymidylate synthase expression as a biomarker for resectable colon cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.
Oncologist. 2017; 22(1): 107-114.

In Process

Reply to L. Casadaban et al.
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.
J Clin Oncol. 2017: JCO2016712646.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.
Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X.
Sci Rep. 2016; 6: 33273.


Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers : a secondary analysis of 2 randomized clinical trials.
Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
JAMA Oncol. 2016.

Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance).
Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR.
Oncologist. 2016; 21(12): 1509-1521.


Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database.
Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.
J Clin Oncol. 2016; 34(2): 144-150.


Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.
Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR, Alliance for Clinical Trials in O.
Int J Cancer. 2016; 139(5): 986-995.


Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H, Ohio Colorectal Cancer Prevention Initiative Study G.
JAMA Oncol. 2016.

Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in Cancer and Leukemia Group B 9581 (Alliance).
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.
J Clin Oncol. 2016; 34(25): 3047-3053.


Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB.
Pharmacogenet Genomics. 2016; 26(3): 133-137.


Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.
Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, Bekaii-Saab T.
Genet Med. 2016; 18(9): 863-868.

In Memoriam: A Tribute to Daniel J. Sargent, Ph.D.
Goldberg RM.
Oncologist. 2016; 21(12): 1540-1541.


The effects of family, dentition, and dental caries on the salivary microbiome.
Foxman B, Luo T, Srinivasan U, Ramadugu K, Wen A, Goldberg D, Shedden KA, Crout RJ, McNeil DW, Weyant RJ, Marazita ML.
Ann Epidemiol. 2016; 26(5): 348-354.


CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers.
Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, 3rd, Goldberg RM.
J Clin Oncol. 2016; 34(23): 2736-2742.


Primary tumor sidedness as prognostic and predictive biomarker in metastatic colorectal cancer: further validation of a potentially practice-changing variable.
Ciombor KK, Goldberg RM.
JAMA Oncol. 2016.

Highlights in gastrointestinal (colorectal) cancer treatment: the primary tumor sidedness debate and advances in immunotherapy.
Ciombor KK, Goldberg RM.
JAMA Oncol. 2016; 2(12): 1537-1538.

Colorectal clinical trials: what is on the horizon?
Ahn DH, Goldberg RM.
Future Oncol. 2016; 12(4): 525-531.


Racial differences in BRAF/KRAS mutation rates and survival in stage III colon cancer patients.
Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in O.
J Natl Cancer Inst. 2015; 107(10).

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.
Lancet Oncol. 2015; 16(8): 937-948.

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
Gastroenterology. 2015; 148(1): 88-99.


Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance).
Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in O.
Clin Cancer Res. 2015; 21(23): 5294-5304.


Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Diaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ.
J Clin Oncol. 2015; 33(1): 22-28.


Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG.
J Clin Oncol. 2015; 33(1): 36-41.


Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Nordlinger BM, Poston GJ, Goldberg RM.
J Clin Oncol. 2015; 33(3): 241-243.

Reply to J.N. Primrose et al and C.-H. Kohne.
Nordlinger BM, Poston GJ, Goldberg RM.
J Clin Oncol. 2015; 33(21): 2408-2409.

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS.
J Natl Cancer Inst. 2015; 107(1): 345.


PD-1 blockade in tumors with mismatch-repair deficiency.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA, Jr.
N Engl J Med. 2015; 372(26): 2509-2520.


Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
Lamont EB, Schilsky RL, He Y, Muss H, Cohen HJ, Hurria A, Meilleur A, Kindler HL, Venook A, Lilenbaum R, Niell H, Goldberg RM, Joffe S, Alliance for Clinical Trials in O.
J Natl Cancer Inst. 2015; 107(1): 336.


Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.
Goodson WH, III, Lowe L, Carpenter DO, Gilbertson M, Ali AM, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami G, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, H.A. H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondracek J, Raju J, Roman J, Wise JP, Sr., Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko JE, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart M, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson P, Dent P, Heneberg P, Darbre P, P.S. L, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Hamid RA, Langie SA, Eltom S, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engstrom W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu ZW.
Carcinogenesis. 2015; 36 Suppl 1: S254-S296.


Genomic profiling in gastrointestinal cancer: are we ready to use these data to make treatment decisions?
Goldberg RM.
Oncologist. 2015; 20(12): 1448-1456.


Recent therapeutic advances in the treatment of colorectal cancer.
Ciombor KK, Wu C, Goldberg RM.
Annu Rev Med. 2015; 66: 83-95.

Update on anti-angiogenesis therapy in colorectal cancer.
Ciombor KK, Goldberg RM.
Curr Colorectal Cancer Rep. 2015; 11(6): 378-387.


Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T.
Ann Surg Oncol. 2015; 22(4): 1153-1159.


The efficacy of adjuvant chemotherapy in patients with stage II/III resected rectal cancer treated with neoadjuvant chemoradiation therapy.
Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T.
Am J Clin Oncol. 2015.


KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in O.
Clin Cancer Res. 2014; 20(11): 3033-3043.


CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Jr., Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in O.
Gastroenterology. 2014; 147(3): 637-645.


Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.
Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H.
PLoS One. 2014; 9(4): e94727.


MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Jr., Maizels N.
PLoS One. 2014; 9(10): e108483.


Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
O'Neil BH, Cainap C, Van Cutsem E, Gorbunova V, Karapetis CS, Berlin J, Goldberg RM, Qin Q, Qian J, Ricker JL, Fischer J, McKee MD, Carlson DM, Kim TW.
Clin Colorectal Cancer. 2014; 13(3): 156-163 e152.

Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management.
Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston M.
J Gastrointest Surg. 2014; 18(12): 2186-2191.


A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH.
Cancer Chemother Pharmacol. 2014; 74(1): 117-123.


Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.
Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C, Aide et Recherche en Cancerologie Digestive F.
J Clin Oncol. 2014; 32(27): 2975-2984.


DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB.
J Natl Cancer Inst. 2014; 106(12).


Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH, Jr., Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in O.
Clin Colorectal Cancer. 2014; 13(2): 100-109.


Prostate cancer incidence in males with Lynch syndrome.
Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM.
Genet Med. 2014; 16(7): 553-557.


Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in O.
J Natl Cancer Inst. 2014; 106(7).


How can next-generation sequencing (genomics) help us in treating colorectal cancer?
Ciombor KK, Haraldsdottir S, Goldberg RM.
Curr Colorectal Cancer Rep. 2014; 10(4): 372-379.


Current evidence and controversiers in the incorporation of biologics for metastatic colorectal cancer.
Ciombor KK, Goldberg RM.
Hepatic Oncol. 2014; 1(3): 331-345.

Caries resistance as a function of age in an initially caries-free population.
Wen A, Goldberg D, Marrs CF, Weyant RJ, Marazita ML, Srinivasan U, Zhang L, Crout RJ, McNeil DW, Foxman B.
J Dent Res. 2012; 91(7): 671-675.


Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory Acute Myelogenous Leukemia: results from the CLASSIC I trial.
Faderl S, Wetzler M, Rizzieri DA, Schiller GJ, Jagasia MH, Stuart RK, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari PN, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM.
J Clin Oncol. 2012; 30(20): 2492-2499.


ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle.
Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL.
Cell. 2011; 144(4): 526-538.


Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.
Deriziotis P, Andre R, Smith DM, Goold R, Kinghorn KJ, Kristiansen M, Nathan JA, Rosenzweig R, Krutauz D, Glickman MH, Collinge J, Goldberg AL, Tabrizi SJ.
EMBO J. 2011; 30(15): 3065-3077.


A conserved F box regulatory complex controls proteasome activity in Drosophila.
Bader M, Benjamin S, Wapinski OL, Smith DM, Goldberg AL, Steller H.
Cell. 2011; 145(3): 371-382.


Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions.
Yu Y, Smith DM, Kim HM, Rodriguez V, Goldberg AL, Cheng Y.
EMBO J. 2010; 29(3): 692-702.


Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases.
Rabl J, Smith DM, Yu Y, Chang SC, Goldberg AL, Cheng Y.
Mol Cell. 2008; 30(3): 360-368.

Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry.
Smith DM, Chang SC, Park S, Finley D, Cheng Y, Goldberg AL.
Mol Cell. 2007; 27(5): 731-744.


ATP-induced structural transitions in PAN, the proteasome-regulatory ATPase complex in Archaea.
Horwitz AA, Navon A, Groll M, Smith DM, Reis C, Goldberg AL.
J Biol Chem. 2007; 282(31): 22921-22929.

Proteasomes and their associated ATPases: a destructive combination.
Smith DM, Benaroudj N, Goldberg AL.
J Struct Biol. 2006; 156(1): 72-83.

ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins.
Smith DM, Kafri G, Cheng Y, Ng D, Walz T, Goldberg AL.
Mol Cell. 2005; 20(5): 687-698.

Residency training in preventive medicine: challenges and opportunities.
Ducatman AM, Vanderploeg JM, Johnson M, Rubin J, Harber P, Sokas R, Harmon RG, Rumm P, Nilson E, Batalden P, Merchant G, Krauss M, Goldberg RL, Valdez M, Dismuke SE, Wagner GR, Leniek K, Rosenthal J.
Am J Prev Med. 2005; 28(4): 403-412.

p38 MAPK activation by TGF-beta1 increases MLC phosphorylation and endothelial monolayer permeability.
Goldberg PL, MacNaughton DE, Clements RT, Minnear FL, Vincent PA.
Am J Physiol Lung Cell Mol Physiol. 2002; 282(1): L146-L154.

Rearrangement of adherens junctions by transforming growth factor-beta1: role of contraction.
Hurst V, IV, Goldberg PL, Minnear FL, Heimark RL, Vincent PA.
Am J Physiol. 1999; 276(4 Pt 1): L582-L595.

Cocaine cytotoxicity in serum-free environment: C6 glioma cell culture.
Gu J, Yassini PR, Goldberg G, Zhu W, Konat GW, Wiggins RC.
Neurotoxicology. 1993; 14(1): 19-22.

Secreted proteases. Regulation of their activity and their possible role in metastasis.
Goldberg GI, Frisch SM, He C, Wilhelm SM, Reich R, Collier IE.
Ann N Y Acad Sci. 1990; 580: 375-384.

Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells.
Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg GI.
Oncogene. 1990; 5(1): 75-83.